Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Emma Börgeson

Universitetslektor/biträdande

Emma Börgeson
Universitetslektor/biträdande
Emma.Borgeson@wlab.gu.se

Postal Address: Su sahlgrenska, 41345 Göteborg
Visiting Address: Blå stråket 5 b wallenberglab/su , 41345 Göteborg


Department of Molecular and Clinical Medicine at Institute of Medicine (More Information)
SU Sahlgrenska
413 45 Göteborg
Fax: +46 31823762
Visiting Address: Blå stråket 5 B Wallenberglab/SU , 413 45 Göteborg

About Emma Börgeson

Assistant Professor, Principal Investigator

Emma Börgeson is an assistant professor in the Department of Molecular and Clinical Medicine. She joined the faculty as a tenure-track fellow in the Wallenberg Centre for Molecular and Translational Medicine (WCMTM) at Gothenburg University. Dr. Börgeson leads a small but dedicated translational research team, investigating the therapeutic potential of immunomodulation in obesity-related cardiometabolic pathophysiology.

After completing her PhD in medicine at University College Dublin in 2011, Dr Börgeson received a Marie Curie fellowship from the European Commission to do a three-year post doc at the University of San Diego (UCSD). There, she investigated the therapeutic potential of immunomodulation in models of obesity, with a particular focus on chronic kidney disease. Her current research focus is to identify the anti-inflammatory mechanisms that control obesity-related cardiometabolic disease and to translate these findings to human pathophysiology.

Emma Börgeson has received numerous honors and awards.

Honors & Awards

  • Junior Investigator Award, International Conference on Phospholipase A2 and Lipid Mediators, San Diego. 2016
  • Emerging Leaders in Nutritional Sciences, Experimental Biology, San Diego. 2016
  • Nominated for the Hasselblad Foundation Award for women scientists, Sweden. 2015
  • Highlighted poster, Bioactive Lipids in Inflammation & Diseases, Puerto Rico. 2013
  • Nominated for Roche National Researcher of the Year, Ireland. 2013
  • Honorary Directors Prize due to special distinction, UCD Conway festival, Ireland. 2013
  • Best moderated poster, Diabetes & Vascular biology, UCD Conway festival, Ireland. 2013
  • Best scientific presentation, Irish Society of Nephrology, Ireland. 2013
  • Outstanding junior career progression, ERA-EDTA ‘Molecular Targets in Renal Disease’ Symposia, Germany. 2011

Main Research

We are a translational research team, investigating the underlying disease mechanisms of obesity and cardiometabolic disease, with a special interest in inflammatory resolution.

Inflammation is a key driver of obesity-induced cardiometabolic pathophysiology and consists of two phases: an initial acute phase followed by a resolving phase. The latter is actively regulated by specialized pro-resolving lipid mediators (SPMs). Lipoxins are one group of SPMs that act through defined receptors to promote resolution of inflammation.

The overall aim of our research is to investigate and harness the therapeutic potential of lipoxins. Our studies suggest that treatment with lipoxins attenuates obesity-induced adipose inflammation and subsequent development of systemic disease (Börgeson et al, Cell Metabolism, 2015). We are currently investigating the underlying mechanisms that mediate this protection, and whether our results from preclinical models can be translated to human pathophysiology.

We combine experimental studies with clinical basic research to address our hypotheses in a translational manner. We use ex vivo culture of tissue biopsies, which provide valuable “proof-of-principle” evidence to correlate our experimental data with human physiology. This translational approach requires state-of-the art experimental and clinical facilities, as well as a broad network of expertise, made possible via our collaborators. For more information on our research, please visit Borgeson lab.

Group Members

  • Matúš Soták, PhD: Postdoctoral Fellow
  • Meenu Rohini Rajan, PhD: Postdoctoral Fellow
  • Fredrik Barrenäs, PhD: Senior Research Associate
  • Madison Clark: Undergraduate Researcher
  • Emelie Shehadeh: Undergraduate Researcher

Key Publications

Key original papers

Börgeson E, Wallenius V, Syed GH, Darshi M, Lantero Rodriguez J, Biörserud C, Ragnmark Ek M, Björklund P, Quiding-Järbrink M, Fändriks L, Godson C, Sharma K.
AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin.
Diabetologia. 60(4):729-739 (2017).

Börgeson E, Johnsson A, Lee Y.S., Till A, Syed H, Ali-Shah, Guiry P, Dalli D, Colas R, Serhan CN, Godson C, Sharma K.
Lipoxin A4 attenuates obesity-induced adipose inflammation, liver and kidney disease.
Cell Metabolism. 7;22(1):125-37 (2015).

Börgeson E, McGillicuddy FC, Harford KA, Corrigan N, Higgins DF, Maderna P, Roche HM, Godson C.
Lipoxin A4 attenuates adipose inflammation.
FASEB Journal. 26(10):4287-94 (2012).

Börgeson E, Docherty NG, Murphy M, Rodgers K, Ryan A, O'Sullivan TP, Guiry PJ, Goldschmeding R, Higgins DF, Godson C.
Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis.
FASEB Journal. 25(9):2967-79. (2011).

Börgeson E, Lönn J, Bergström I, Brodin VP, Ramström S, Nayeri F, Särndahl E, Bengtsson T.
Lipoxin A4 inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression.
Infection and Immunity 79(4):1489-97. (2011).

Key review papers

Börgeson E.
The role of lipoxins in cardiometabolic physiology and disease.
Cardiovascular Endocrinology Journal, October 28, doi: 10.1097/XCE.0000000000000068. (2015).

Börgeson E, Sharma K.
Obesity, immunomodulation and chronic kidney disease.
Current Opinion in Pharmacol. 13(4):618-24. (2013).

Börgeson E, Godson C.
Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.
Frontiers in Immunology, 18;3:318. (2012).


For more information, please visit:
Börgesonlab.org

Latest publications

Obesity-induced changes in lipid mediators persist after weight loss
A. Hernandez-Carretero, N. Weber, M. R. La Frano, W. Ying, Juan Lantero Rodriguez et al.
International Journal of Obesity, Journal article 2018
Journal article

The role of lipoxins in cardiometabolic physiology and disease
Emma Börgeson
Cardiovascular Endocrinology, Review article 2016
Review article

The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose metabolism in mice.
Linlin Zhong, Yun Ding, Gautam Bandyopadhyay, Jo Waaler, Emma Börgeson et al.
Diabetologia, Journal article 2016
Journal article

Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease.
Emma Börgeson, Andrew M F Johnson, Yun Sok Lee, Andreas Till, Gulam Hussain Syed et al.
Cell metabolism, Journal article 2015
Journal article

Obesity, immunomodulation and chronic kidney disease.
Emma Börgeson, Kumar Sharma
Current opinion in pharmacology, Review article 2013
Review article

IHG-1 must be localised to mitochondria to decrease Smad7 expression and amplify TGF-β1-induced fibrotic responses.
James B Corcoran, Sarah McCarthy, Brenda Griffin, Andrew Gaffney, Una Bhreathnach et al.
Biochimica et biophysica acta, Journal article 2013
Journal article

Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1.
Emma Börgeson, Eoin P Brennan, Karen A Nolan, Oisín S Gough, Caitríona M McEvoy et al.
Journal of the American Society of Nephrology : JASN, Journal article 2013
Journal article

Lipoxin A4 attenuates adipose inflammation.
Emma Börgeson, Fiona C McGillicuddy, Karen A Harford, Niamh Corrigan, Debra F Higgins et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Journal article 2012
Journal article

Showing 1 - 10 of 13

2018

Obesity-induced changes in lipid mediators persist after weight loss
A. Hernandez-Carretero, N. Weber, M. R. La Frano, W. Ying, Juan Lantero Rodriguez et al.
International Journal of Obesity, Journal article 2018
Journal article

2017

2016

The role of lipoxins in cardiometabolic physiology and disease
Emma Börgeson
Cardiovascular Endocrinology, Review article 2016
Review article

The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose metabolism in mice.
Linlin Zhong, Yun Ding, Gautam Bandyopadhyay, Jo Waaler, Emma Börgeson et al.
Diabetologia, Journal article 2016
Journal article

2015

Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease.
Emma Börgeson, Andrew M F Johnson, Yun Sok Lee, Andreas Till, Gulam Hussain Syed et al.
Cell metabolism, Journal article 2015
Journal article

2013

Obesity, immunomodulation and chronic kidney disease.
Emma Börgeson, Kumar Sharma
Current opinion in pharmacology, Review article 2013
Review article

IHG-1 must be localised to mitochondria to decrease Smad7 expression and amplify TGF-β1-induced fibrotic responses.
James B Corcoran, Sarah McCarthy, Brenda Griffin, Andrew Gaffney, Una Bhreathnach et al.
Biochimica et biophysica acta, Journal article 2013
Journal article

Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1.
Emma Börgeson, Eoin P Brennan, Karen A Nolan, Oisín S Gough, Caitríona M McEvoy et al.
Journal of the American Society of Nephrology : JASN, Journal article 2013
Journal article

2012

Lipoxin A4 attenuates adipose inflammation.
Emma Börgeson, Fiona C McGillicuddy, Karen A Harford, Niamh Corrigan, Debra F Higgins et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Journal article 2012
Journal article

Showing 1 - 10 of 13

Page Manager: Karin Allander|Last update: 9/19/2019
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?